



University of Groningen

Mortality and preoperative cardiac function in vascular amputees

Riemersma, Marcel; Dijkstra, Pieter U.; van Veldhuisen, Dirk; Muskiet, Frits; van den Dungen, Johannes; Geertzen, Jan H.B.

Published in: Clinical Rehabilitation

DOI:

10.1177/0269215507079864

IMPORTANT NOTE: You are advised to consult the publisher's version (publisher's PDF) if you wish to cite from it. Please check the document version below.

Document Version Publisher's PDF, also known as Version of record

Publication date:

Link to publication in University of Groningen/UMCG research database

Citation for published version (APA):

Riemersma, M., Dijkstra, P. U., van Veldhuisen, D. J., Muskiet, F. A. J., van den Dungen, J. A. M. M., & Geertzen, J. H. B. (2008). Mortality and preoperative cardiac function in vascular amputees: an N-terminal pro-bran natrius peptide (NT-proBNP) pilot study. Clinical Rehabilitation, 22(1), 56-59. DOI: 10.1177/0269215507079864

Copyright

Other than for strictly personal use, it is not permitted to download or to forward/distribute the text or part of it without the consent of the author(s) and/or copyright holder(s), unless the work is under an open content license (like Creative Commons).

Take-down policy

If you believe that this document breaches copyright please contact us providing details, and we will remove access to the work immediately and investigate your claim.

Downloaded from the University of Groningen/UMCG research database (Pure): http://www.rug.nl/research/portal. For technical reasons the number of authors shown on this cover page is limited to 10 maximum.

Download date: 10-02-2018

Clinical Rehabilitation

http://cre.sagepub.com

Mortality and preoperative cardiac function in vascular amputees: an N-terminal pro-brain natriuretic peptide (NT-proBNP) pilot study

Marcel Riemersma, Pieter U. Dijkstra, Dirk Jan van Veldhuisen, Frits A.J. Muskiet, Jan A.M.M. van den Dungen and Jan H.B. Geertzen

Clin Rehabil 2008; 22; 56 originally published online Nov 29, 2007; DOI: 10.1177/0269215507079864

The online version of this article can be found at: http://cre.sagepub.com/cgi/content/abstract/22/1/56

Published by: \$SAGE Publications http://www.sagepublications.com

Additional services and information for Clinical Rehabilitation can be found at:

Email Alerts: http://cre.sagepub.com/cgi/alerts

Subscriptions: http://cre.sagepub.com/subscriptions

Reprints: http://www.sagepub.com/journalsReprints.nav

Permissions: http://www.sagepub.com/journalsPermissions.nav

Citations (this article cites 11 articles hosted on the SAGE Journals Online and HighWire Press platforms): http://cre.sagepub.com/cgi/content/refs/22/1/56

Mortality and preoperative cardiac function in vascular amputees: an N-terminal pro-brain natriuretic peptide (NT-proBNP) pilot study

Marcel Riemersma, Pieter U Dijkstra Center for Rehabilitation, Dirk Jan van Veldhuisen Department of Cardiology, Frits AJ Muskiet Pathology and Laboratory Medicine, Jan AMM van den Dungen Department of Vascular Surgery and Jan HB Geertzen Center for Rehabilitation, University Medical Center Groningen, University of Groningen, Groningen, The Netherlands

Received 6th March 2007; manuscript accepted 20th March 2007.

Objective: To determine preoperative ventricular function in vascular amputees by measuring N-terminal pro-brain natriuretic peptide (NT-proBNP) and to analyse the relationship between NT-proBNP levels and 30-day postoperative mortality.

Design: Prospective pilot study.

Subjects and methods: In 19 patients planned for a lower limb amputation for non-reconstructable peripheral arterial disease NT-proBNP was measured the day before amputation.

Results: Four amputees died within 30 days after the amputation. In 17 of 19 patients NT-proBNP values were found more than 2 standard deviations above the age corrected reference value. Pre-amputation NT-proBNP levels did not differ significantly between non-survivors and survivors (P=0.162).

Conclusion: Preoperative NT-proBNP levels are not significantly related to 30-day mortality after lower limb amputation procedure. Preoperative NT-proBNP levels are very high, indicating that serious ventricular dysfunction may be present in vascular amputees.

Introduction

Peri-operative mortality in lower limb amputees is high.¹ Myocardial infarction is the most common cause of postoperative mortality.² Cardiac function is relevant for the postamputation rehabilitation process because energy expenditure during gait is increased in lower limb amputees.^{3–5} Thus regaining bipedal gait adds an additional level of stress to the heart that

may already be compromised by pre-existing heart disease. On the basis of the above arguments one should pay attention to the presence of heart disease in vascular amputees to prevent complications (mortality) not only in the peri-operative phase but also in the rehabilitation phase.

Recent literature has shown that plasma levels of N-terminal pro-brain natriuretic peptide (NT-proBNP) are elevated in patients with asymptomatic left ventricular systolic dysfunction and NT-proBNP levels are highly accurate for detecting left ventricular failure. Elevated NT-proBNP levels might also be a biomarker for the early diagnosis of right ventricular systolic dysfunction. Congestive heart failure patients

Address for correspondence: Professor Jan HB Geertzen, Center for Rehabilitation, University Medical Center Groningen, University of Groningen, PO Box 30.001, 9700 RB Groningen, The Netherlands. e-mail: j.h.b.geertzen@rev.umcg.nl

© SAGE Publications 2008 Los Angeles, London, New Delhi and Singapore

10.1177/0269215507079864

with NT-proBNP values levels above median had a one-year mortality of 53% compared with 11% in patients with below-median levels of NT-proBNP.⁸ In fact NT-proBNP was the strongest independent predictor of one-year mortality in patients with acute coronary syndrome.⁹

The aim of this study was to analyse the relationship between preoperative NT-proBNP levels and 30-day mortality in lower limb amputees who are amputated for a vascular disease.

Methods and materials

Nineteen consecutive patients undergoing a lower limb amputation were studied; the amputations were transtibial, transfemoral or through-knee. Amputations were performed in the Vascular Surgery Department at the Nij Smellinghe Hospital in Drachten and University Medical Centre Groningen. Patients were included if they underwent the amputation for non-reconstructable peripheral arterial disease. Demographics and cardiac history were retrieved from the patient charts.

EDTA-anticoagulated blood ($10\,\mathrm{mL}$) was collected by venous puncture the day before the amputation. Blood samples were centrifuged within 2 hours after sampling. Before storage at $-80^{\circ}\mathrm{C}$ $30\,\mu\mathrm{L}$ of an aprotinin solution (protease inhibitor, $10\,000\,\mathrm{kIU/mL}$; Bayer, Germany) per millilitre of plasma was added to the samples. NT-proBNP (electrochemiluminescence immunoassay; Roche Diagnostics) was measured in the week after collection.

Differences in levels of preoperative NT-proBNP between patients who died in the 30-day period after the amputation and patients who survived that period were analysed using Mann–Whitney test. Differences in levels of preoperative NT-proBNP between the patients with different amputations levels were analysed using the Kruskal–Wallis test.

The preoperative NT-proBNP levels in nonsurvivors and survivors were compared with the reference values given by the manufacturer.

Results

Nineteen patients, 6 women and 13 men with a mean age of 69.1 (SD 12.5) years, participated in the study, 15 of whom had a history of cardiac disease such as heart failure, valve disorder, myocardial infarction and atrial fibrillation. In total, five transfemoral, four through-knee and 10 transtibial amputations were performed. Four amputees died within 30 days after the amputation. The median interquartile ranges (IOR), mean values and standard deviations of NT-proBNP are summarized in Table 1. In general, levels of NT-proBNP were high. In total 17 of 19 patients (89%) had NT-proBNP value levels more than 2 SDs above the age-corrected reference value. NT-proBNP levels were higher in non-survivors than in survivors but the difference was not significant. NT-proBNP levels were highest in transfemoral amputees but this difference was not significant (P = 0.248).

Table 1 NT-proBNP levels (ng/L) for the study population (n = 19) and for the different subgroups

	Median	IQR	Mean	SD	<i>P</i> -value
NT-proBNP in total study group	3723	428–6149	6148	8 984	0.400*
Survival					0.162*
Non-survivors $(n=4)$	11 761	1612–3221	15 198	16352	
Survivors (n = 15)	2 471	417–5971	3 734	4 103	
Level of amputation					0.248**
Transfemoral $(n=5)$	5 9 7 1	2069–27 693	13 207	14 908	
Through-knee $(n=4)$	4 477	1909-5920	4 102	2 117	
Transtibial $(n=10)$	823	381–6388	3 4 3 7	4842	

NT-proBNP did not differ significantly between non-survivors and survivors and (30 days)* or between groups with different amputation levels**.

Discussion

NT-proBNP levels in the amputee non-survivor group were very high compared with those of survivors but the difference was not significant. Preoperative NT-proBNP levels were not associated with the level of amputation. Overall NT-proBNP levels were high in 89% of the vascular amputees, indicating that serious cardiac disease may be present.

These high NT-proBNP levels may have clinical importance because cardiac disease in vascular amputees may be underdiagnosed in the preoperative phase for several reasons. First, 25% of vascular amputees have diabetes, which is associated with a generalized hyposensitivity to pain. 10 Therefore silent ischaemia may be a common phenomenon in diabetic amputees with coronary heart disease. Second, non-ambulant patients with peripheral vascular disease fail to exhibit symptoms of coronary disease because the progressive limb pain limits the ability to attain levels of activity necessary to provoke symptoms of cardiac ischaemia. In the pre-amputation phase obviously most attention will be focused on treatment of the life-threatening ischaemic limb and concomitant heart disease may be overlooked. In contrast, in the rehabilitation phase cardiac problems may arise when the amputee starts walking with a prosthesis and the extra energy necessary for walking with a prosthesis cannot be provided by the compromised heart.³⁻⁵

NT-proBNP measurements in this study were not significantly related to 30-day mortality. The chosen follow-up of 30 days may be too short. A longer follow-up of one year might show a statistical significant relationship between preoperative NT-proBNP measurements and mortality in amputees. In these studies NT-proBNP was an independent prognostic factor of one-year mortality in a different population. Because NT-proBNP levels are subject to intraindividual variations these levels may not be accurate enough as the only biomarker to evaluate ventricular function adequately. It

The statistical power of this study is limited by the small number of patients included. In a posthoc sample size calculation, the standard deviation of the population in this study (8984) and the difference in NT-proBNP between non-survivors and survivors was used. This analysis resulted in a total sample size of 22 patients: 11 in each group. Our total sample was too small and the distribution of non-survivors and survivors was not optimal for statistical analysis. However, the date of the current study can be used for sample size calculation in future research focusing on cardiac disease in vascular amputees.

Clinical messages

- Preoperative NT-proBNP levels in vascular amputees are not statistically related to 30-day mortality and level of amputation.
- Preoperative NT-proBNP levels in vascular amputees are high, indicating that serious ventricular disease may be present.

Acknowledgements

Special thanks to Mr Harry Voesten, MD, surgeon at Nij Smellinghe hospital Drachten, for his contribution to this study.

Competing interests

None declared.

References

- 1 Cruz CP, Eidt JF, Capps C, Kirtley L, Moursi MM. Major lower extremity amputations at a Veterans Affairs hospital. *Am J Surg* 2003; **186**: 449–54.
- 2 Aulivola B, Hile CN, Hamdan AD *et al.* Major lower extremity amputation outcome of a modern series. *Arch Surg* 2004; **139**: 395–99.
- Jaegers SMHJ, Vos LDW, Rispens P, Hof AL. The relationship between comfortable and most metabolically efficient walking speed in persons with unilateral above-knee amputation. *Arch Phys Med Rehabil* 1993; 74: 521–25.
- 4 Gailey RS, Wenger MA, Raya M *et al.* Energy-expenditure of trans-tibial amputees during ambulation at self-selected pace. *Prosthet Orthot Int* 1994; **18**: 84–91.

- 5 Czerniecki JM. Rehabilitation in limb deficiency.1. Gait and motion analysis. Arch Phys Med Rehabil 1996; 77: S3–S8.
- 6 McDonagh TA, Robb SD, Murdoch DR et al. Biochemical detection of left-ventricular systolic dysfunction. *Lancet* 1998; 351: 9–13.
- 7 Tulevski II, Groenink M, van der Wall EE et al. Increased brain and atrial natriuretic peptides in patients with chronic right ventricular pressure overload: correlation between plasma neurohormones and right ventricular dysfunction. *Heart* 2001; 86: 27–30.
- 8 Fisher C, Berry C, Blue L, Morton JJ, Hillier C, McMurray JJ. N terminal B-type natriuretic peptide, but not the FP437 putative cardiac hormone relaxin, predicts adverse outcome in patients with chronic heart failure. Eur Heart J 2003: 24: 61.
- 9 James SK, Lindahl B, Siegbahn A et al. N-terminal pro-brain natriuretic peptide and other risk markers for the separate prediction of mortality andsubsequent myocardial infarction in patients with unstable coronary artery disease – a Global Utilization of Strategies to Open occluded arteries (GUSTO)-IV substudy. Circulation 2003; 108: 275–81.
- 10 Umachandran V, Ranjadayalan K, Ambepityia G, Marchant B, Kopelman PG, Timmis AD. The Perception of angina in diabetes – relation to somatic pain threshold and autonomic function. Am Heart J 1991: 121: 1649–54.
- Bruins S, Fokkema MR, Romer JWP *et al.* High intraindividual variation of B-type natriuretic peptide (BNP) and amino-terminal proBNP in patients with stable chronic heart failure. *Clin Chem* 2004: **50**: 2052–58.